Background and Objectives
To evaluate tau PET
C-pyridinyl-butadienyl-benzothiazole 3 (11
C-PBB3) in the 4-repeat (4R)-tauopathies progressive supranuclear palsy (PSP
) and corticobasal syndrome (CBS
Retrospective analysis of 11
C-PBB3 PET in 2, 7, and 2 patients with CBS
, and Alzheimer dementia (AD), respectively. Normalized 11
C-PBB3 uptake in clusters with significant hypometabolism on 18
F-FDG-PET and corresponding atlas-based volumes of interest was compared between diagnostic groups.
In accordance with visually appreciable group differences, 11
C-PBB3 uptake was significantly higher in dorsolateral frontal and motor cortex in CBS
patients and frontal and temporal cortices in AD patients as compared with PSP
patients. Patients with PSP
showed mildly but significantly higher uptake in midbrain compared with AD patients.
In line with known neuropathological changes, the spatial pattern and magnitude of 11
C-PBB3 tau binding differ between CBS
, and AD, which may be of diagnostic utility. Thus, 11
C-PBB3 offers a promising lead structure for development of ligands for tau imaging, including 4R-tauopathies.